Replies to post #4797 on Insmed Inc (INSM)

[Do DD]

Isn't it better to await the preliminary MMD and HARS data in Q2 2007 before going to court?

E.

[bolt08]

Allen and the management team is horrible.

Here are his statements & her is my intereptation.

His statement: The dark cloud of litigation & uncertainty are removed so the market should respond well.

My rebuttal: You removed the dark cloud of litigation & replaced it with the darker cloud of a company without an approved & sellable product.

His statement: They can now go back to being a biotech company & develop drugs which is what a biotech should do.

My rebuttal: The end goal is to sell drugs, not develop drugs.

..I wonder if Young left the company because he disagreed with the so called "settlement"

This POS will be less than 50 cents in a few months. There is no sellable product for many years. They aren't even in a full P2 trial for any indication.

[awass]

I have been invested in this company for a long time (former celtrix shareholder) and I am furious that they have given away the shop. They have moved from a company with an approved product & orphan status to a "concept" that MAY, MAY, go to phase 11. That said, what is a cause for a suit? Even if a suit were successful where would the cash to pay off the claims come from? No sense in enriching lawyers at our expense.

BTW, did anyone notice that Phillip Young is gone? No mention!

I was also surprised by the fact that our president did not understand what a caller said about INSM taking the risk of a phaase 1 & ii investigation and getting 50% of the profits if any while Genentech cold sit back and only had to pony up AFTER the results were in. What a sweet deal!